Abstract
Romiplostim (Nplate - Amgen), a recombinant fusion protein injected subcutaneously, and eltrombopag (Promacta - GlaxoSmithKline), a non-peptide taken orally, have been approved by the FDA for treatment of chronic immune thrombocytopenic purpura (ITP) refractory to corticosteroids, immunoglobulins and/or splenectomy.
MeSH terms
-
Benzoates / administration & dosage
-
Benzoates / adverse effects
-
Benzoates / therapeutic use*
-
Carrier Proteins / administration & dosage
-
Carrier Proteins / adverse effects
-
Carrier Proteins / therapeutic use*
-
Clinical Trials as Topic
-
Dose-Response Relationship, Drug
-
Humans
-
Hydrazines / administration & dosage
-
Hydrazines / adverse effects
-
Hydrazines / therapeutic use*
-
Purpura, Thrombocytopenic, Idiopathic / drug therapy*
-
Pyrazoles / administration & dosage
-
Pyrazoles / adverse effects
-
Pyrazoles / therapeutic use*
-
Receptors, Fc / administration & dosage
-
Receptors, Fc / therapeutic use*
-
Recombinant Fusion Proteins
-
Thrombopoietin
Substances
-
Benzoates
-
Carrier Proteins
-
Hydrazines
-
Pyrazoles
-
Receptors, Fc
-
Recombinant Fusion Proteins
-
Thrombopoietin
-
romiplostim
-
eltrombopag